Direct
NAV (06-Sep-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹143 Cr
Expense Ratio
0.65%
ISIN
INF03VN01886
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
About this fund
As of 06-Sep-24, it has a Net Asset Value (NAV) of ₹12.94, Assets Under Management (AUM) of 143.32 Crores, and an expense ratio of 0.65%.
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 29.38% since inception.
- The fund's asset allocation comprises around 87.80% in equities, 0.00% in debts, and 12.20% in cash & cash equivalents.
- You can start investing in WhiteOak Capital Pharma and Healthcare Fund Direct Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+29.38%
— (Cat Avg.)
Portfolio Summaryas of 31st July 2024
| Equity | ₹125.84 Cr | 87.80% |
| Others | ₹17.48 Cr | 12.20% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹11.91 Cr | 8.31% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹10.07 Cr | 7.02% |
| Zydus Lifesciences Ltd | Equity | ₹7.69 Cr | 5.36% |
| Divi's Laboratories Ltd | Equity | ₹7.13 Cr | 4.97% |
| Cipla Ltd | Equity | ₹6.58 Cr | 4.59% |
| Torrent Pharmaceuticals Ltd | Equity | ₹5.83 Cr | 4.07% |
| Dr Reddy's Laboratories Ltd | Equity | ₹4.88 Cr | 3.40% |
| Emcure Pharmaceuticals Ltd | Equity | ₹4.64 Cr | 3.24% |
| Aurobindo Pharma Ltd | Equity | ₹4.49 Cr | 3.14% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹4.46 Cr | 3.11% |
| Ajanta Pharma Ltd | Equity | ₹4.36 Cr | 3.04% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹3.98 Cr | 2.78% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹3.82 Cr | 2.66% |
| Neuland Laboratories Limited | Equity | ₹3.82 Cr | 2.66% |
| Poly Medicure Ltd | Equity | ₹3.79 Cr | 2.65% |
| Fortis Healthcare Ltd | Equity | ₹3.69 Cr | 2.58% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹3.47 Cr | 2.42% |
| Lupin Ltd | Equity | ₹3.29 Cr | 2.30% |
| Biocon Ltd | Equity | ₹3.27 Cr | 2.28% |
| Piramal Pharma Ltd | Equity | ₹2.73 Cr | 1.91% |
| Dr. Lal PathLabs Ltd | Equity | ₹2.71 Cr | 1.89% |
| Gland Pharma Ltd | Equity | ₹2.61 Cr | 1.82% |
| Shilpa Medicare Ltd | Equity | ₹2.42 Cr | 1.69% |
| AstraZeneca Pharma India Ltd | Equity | ₹2.35 Cr | 1.64% |
| Wockhardt Ltd | Equity | ₹2.34 Cr | 1.63% |
| Ami Organics Ltd | Equity | ₹2.22 Cr | 1.55% |
| RPG Life Sciences Ltd | Equity | ₹2.05 Cr | 1.43% |
| 364 DTB 17102024 | Bond - Gov't/Treasury | ₹1.97 Cr | 1.38% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹1.97 Cr | 1.38% |
| Suven Pharmaceuticals Ltd | Equity | ₹1.91 Cr | 1.33% |
| FDC Ltd | Equity | ₹1.66 Cr | 1.16% |
| Net Receivables / (Payables) | Cash | ₹1.65 Cr | 1.15% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹1.6 Cr | 1.11% |
| Supriya Lifescience Ltd | Equity | ₹1.55 Cr | 1.08% |
| Granules India Ltd | Equity | ₹1.46 Cr | 1.02% |
| Gufic Biosciences Ltd | Equity | ₹1.45 Cr | 1.01% |
| Strides Pharma Science Ltd | Equity | ₹1.38 Cr | 0.96% |
| 182 DTB 22082024 | Bond - Gov't/Treasury | ₹1.25 Cr | 0.87% |
| Sanofi Consumer He | Equity | ₹1.08 Cr | 0.75% |
| Indegene Ltd | Equity | ₹1.06 Cr | 0.74% |
| Innova Captab Ltd | Equity | ₹0.97 Cr | 0.67% |
| Neogen Chemicals Ltd | Equity | ₹0.77 Cr | 0.53% |
| 91 DTB 26092024 | Bond - Gov't/Treasury | ₹0.5 Cr | 0.35% |
| Mankind Pharma Ltd | Equity | ₹0.28 Cr | 0.19% |
| India (Republic of) | Bond - Short-term Government Bills | ₹0.1 Cr | 0.07% |
| 182 DTB 24102024 | Bond - Gov't/Treasury | ₹0.1 Cr | 0.07% |
Allocation By Market Cap (Equity)
Large Cap Stocks
25.37%
Mid Cap Stocks
26.41%
Small Cap Stocks
28.63%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹117.96 Cr | 82.30% |
| Basic Materials | ₹2.99 Cr | 2.09% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Fund Managers
Piyush Baranwal
Since February 2024
Ramesh Mantri
Since February 2024
Dheeresh Pathak
Since February 2024
Naitik Shah
Since April 2024
Additional Scheme Detailsas of 31st July 2024
ISIN | INF03VN01886 | Expense Ratio | 0.65% | Exit Load | 1.00% | Fund Size | ₹143 Cr | Age | 06 Feb 2024 | Lumpsum Minimum | ₹500 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
What is the portfolio composition of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
Who manages the WhiteOak Capital Pharma and Healthcare Fund Direct Growth?
- Piyush Baranwal
- Ramesh Mantri
- Dheeresh Pathak
- Naitik Shah
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.